§01
How TGA regulates AI-enabled software
AI-enabled software that meets the definition of a medical device is regulated under the Therapeutic Goods (Medical Devices) Regulations 2002, as amended in 2021. Devices are classified using risk-based rules (Class I → Class III / AIMD) with software-specific classification rules (Rules 4.1–4.4 / Schedule 2) introduced in the reform. AI does not change classification logic · it raises the evidence bar, particularly around data, validation, transparency and post-market monitoring.
- Most diagnostic AI lands Class IIa or IIb under the software classification rules.
- Sponsors must hold a conformity assessment (TGA or comparable overseas regulator) before ARTG inclusion.
- Evidence package: intended purpose, dataset, validation, human factors, post-market plan.
- Australian Unique Device Identifier (AusUDI) work is rolling out and applies to software devices.
§02
Evidence requirements for AI software
The TGA evidence guidance for AI software sets out what a sponsor must demonstrate over and above the standard software evidence: clarity of intended purpose, representativeness and quality of training and test data, transparency to users about model behaviour and limitations, and a post-market plan that detects drift and adverse events. It is explicitly aligned with the IMDRF GMLP guiding principles.
- Document data provenance, inclusion/exclusion criteria, and subgroup performance.
- Demonstrate validation on data that is representative of the Australian deployment context.
- Provide transparency information · what the model does, what it does not do, its known failure modes.
- Operate a post-market monitoring plan with thresholds, escalation, and reporting.
§03
Change control: significant change triggers re-inclusion
TGA does not yet have a formal PCCP-equivalent. The default rule is that a significant change to an AI medical device · including retraining that materially alters performance or intended use · requires a new ARTG inclusion or, at minimum, a change notification to TGA. Sponsors are expected to define, in their QMS, what constitutes a significant change for their specific device. AI-specific change-control guidance is on the agency's known workplan.
§04
Practical posture
Australia is a high-leverage market: the rules are pragmatic, the comparable-overseas-regulator pathway accelerates entry for devices already cleared by FDA / EU / HC, and the evidence expectations are well-telegraphed. The risk is treating it as a copy-paste market. Validation evidence, intended purpose statements, and post-market plans need to be reworked for the Australian context, and change control needs to be planned defensively until formal PCCP guidance lands.